HC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $620
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Andrew S. Fein maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $568 to $620.
HC Wainwright & Co. analyst Andrew S. Fein maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $568 to $620.